Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mahim Jain is active.

Publication


Featured researches published by Mahim Jain.


Molecular Psychiatry | 2010

A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication

Mauricio Arcos-Burgos; Mahim Jain; Maria T. Acosta; Shively S; Horia Stanescu; Deeann Wallis; Sabina Domené; Jorge I. Vélez; Karkera Jd; Joan Z. Balog; Kate Berg; Robert Kleta; William A. Gahl; Erich Roessler; Robert Long; Lie J; David Pineda; Ana Londoño; Juan David Palacio; Andres Arbelaez; Francisco Lopera; Josephine Elia; Hakon Hakonarson; Stefan Johansson; Per M. Knappskog; Jan Haavik; Marta Ribasés; Bru Cormand; Mònica Bayés; M. Casas

Attention-Deficit/Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting that about 80% of phenotypic variance is due to genetic factors. We used the integration of statistical and functional approaches to discover a novel gene that contributes to ADHD. For our statistical approach, we started with a linkage study based on large multigenerational families in a population isolate, followed by fine mapping of targeted regions using a family-based design. Family- and population-based association studies in five samples from disparate regions of the world were used for replication. Brain imaging studies were performed to evaluate gene function. The linkage study discovered a genome region harbored in the Latrophilin 3 gene (LPHN3). In the world-wide samples (total n=6360, with 2627 ADHD cases and 2531 controls) statistical association of LPHN3 and ADHD was confirmed. Functional studies revealed that LPHN3 variants are expressed in key brain regions related to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are associated with response to stimulant medication. Linkage and replicated association of ADHD with a novel non-candidate gene (LPHN3) provide new insights into the genetics, neurobiology, and treatment of ADHD.


Biological Psychiatry | 2007

Attention-Deficit/Hyperactivity Disorder and Comorbid Disruptive Behavior Disorders: Evidence of Pleiotropy and New Susceptibility Loci

Mahim Jain; Palacio Lg; F. Xavier Castellanos; Juan David Palacio; David Pineda; María Isabel Restrepo; Juan Fernando Muñoz; Francisco Lopera; Deeann Wallis; Kate Berg; Joan E. Bailey-Wilson; Mauricio Arcos-Burgos; Maximilian Muenke

BACKGROUND Attention-deficit/hyperactivity disorder (ADHD) comorbid with oppositional defiant disorder (ODD) or conduct disorder (CD) and substance abuse/dependence seems to represent a specific subset within the phenotypic ADHD spectrum. METHODS We applied complex segregation and linkage analyses in a set of multigenerational families densely segregating ADHD comorbid with ODD, CD, alcohol abuse/dependence, and nicotine dependence. RESULTS Our data suggest that ADHD cosegregates with disruptive behaviors as a unique, phenotypically variable trait as evidenced by highly significant pair-wise linkages among: ADHD and ODD (logarithm of odds [LOD]=14.19), ADHD and CD (LOD=5.34), ODD and CD (LOD=6.68), and CD and alcohol abuse/dependence (LOD=3.98). In addition to previously reported ADHD susceptibility loci, we found evidence of linkage for comorbid ADHD phenotypes to loci at 8q24, 2p21-22.3, 5p13.1-p13.3, 12p11.23-13.3, 8q15, and 14q21.1-22.2. These results were replicated with an affected status phenotype derived from latent class clusters. CONCLUSIONS Patterns of cosegregation of ADHD with comorbidities can inform our understanding of the inheritance patterns not only of ADHD but also of disruptive behavioral disorders and alcohol abuse/dependence. Refining the comorbid ADHD phenotype by determining the cosegregation profile of specific comorbidities might be a powerful tool for defining significant regions of linkage.


American Journal of Human Genetics | 2014

Mutations in PURA Cause Profound Neonatal Hypotonia, Seizures, and Encephalopathy in 5q31.3 Microdeletion Syndrome

Seema R. Lalani; Jing Zhang; Christian P. Schaaf; Chester W. Brown; Pilar L. Magoulas; Anne Chun Hui Tsai; Areeg El-Gharbawy; Klaas J. Wierenga; Dennis Bartholomew; Chin-To Fong; Tina Barbaro-Dieber; Mary K. Kukolich; Lindsay C. Burrage; Elise G. Austin; Kory Keller; Matthew Pastore; Fabio Fernandez; Timothy Lotze; Angus A. Wilfong; Gabriela Purcarin; Wenmiao Zhu; William J. Craigen; Marianne McGuire; Mahim Jain; Erin Cooney; Mahshid S. Azamian; Matthew N. Bainbridge; Donna M. Muzny; Eric Boerwinkle; Richard E. Person

5q31.3 microdeletion syndrome is characterized by neonatal hypotonia, encephalopathy with or without epilepsy, and severe developmental delay, and the minimal critical deletion interval harbors three genes. We describe 11 individuals with clinical features of 5q31.3 microdeletion syndrome and de novo mutations in PURA, encoding transcriptional activator protein Pur-α, within the critical region. These data implicate causative PURA mutations responsible for the severe neurological phenotypes observed in this syndrome.


Molecular Psychiatry | 2012

A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD

Mahim Jain; Jorge I. Vélez; Maria T. Acosta; Louis Guillermo Palacio; Joan Z. Balog; Erich Roessler; David Pineda; Ana Londoño; Juan Davis Palacio; Andres Arbelaez; Francisco Lopera; Josephine Elia; Hakon Hakonarson; Christiane Seitz; Christine M. Freitag; Haukur Palmason; Jobst Meyer; Marcel Romanos; Susanne Walitza; U. Hemminger; Andreas Warnke; Jasmin Romanos; Tobias J. Renner; Christian Jacob; Klaus-Peter Lesch; James M. Swanson; Francisco Xavier Castellanos; Joan E. Bailey-Wilson; Mauricio Arcos-Burgos; Maximilian Muenke

In previous studies of a genetic isolate, we identified significant linkage of attention deficit hyperactivity disorder (ADHD) to 4q, 5q, 8q, 11q and 17p. The existence of unique large size families linked to multiple regions, and the fact that these families came from an isolated population, we hypothesized that two-locus interaction contributions to ADHD were plausible. Several analytical models converged to show significant interaction between 4q and 11q (P<1 × 10−8) and 11q and 17p (P<1 × 10−6). As we have identified that common variants of the LPHN3 gene were responsible for the 4q linkage signal, we focused on 4q–11q interaction to determine that single-nucleotide polymorphisms (SNPs) harbored in the LPHN3 gene interact with SNPs spanning the 11q region that contains DRD2 and NCAM1 genes, to double the risk of developing ADHD. This interaction not only explains genetic effects much better than taking each of these loci effects by separated but also differences in brain metabolism as depicted by proton magnetic resonance spectroscopy data and pharmacogenetic response to stimulant medication. These findings not only add information about how high order genetic interactions might be implicated in conferring susceptibility to develop ADHD but also show that future studies of the effects of genetic interactions on ADHD clinical information will help to shape predictive models of individual outcome.


American Journal of Medical Genetics Part A | 2009

A Novel SIX3 Mutation Segregates With Holoprosencephaly in a Large Family

Benjamin D. Solomon; Felicitas Lacbawan; Mahim Jain; Sabina Domené; Erich Roessler; Cynthia A. Moore; William B. Dobyns; Maximilian Muenke

Holoprosencephaly is the most common structural malformation of the forebrain in humans and has a complex etiology including chromosomal aberrations, single gene mutations and environmental components. Here we present the pertinent clinical findings among members of an unusually large kindred ascertained over 15 years ago following the evaluation and subsequent genetic work‐up of a female infant with congenital anomalies. A genome‐wide scan and linkage analysis showed only suggestive evidence of linkage to markers on chromosome 2 among the most likely of several pedigree interpretations. We now report that a novel missense mutation in the SIX3 holoprosencephaly gene is the likely cause in this family. Molecular genetic analysis and/or clinical characterization now show that at least 15 members of this family are presumed SIX3 mutation gene carriers, with clinical manifestations ranging from phenotypically normal adults (non‐penetrance) to alobar holoprosencephaly incompatible with postnatal life. This particular family represents a seminal example of the variable manifestations of gene mutations in holoprosencephaly and difficulties encountered in their elucidation. Published 2009 Wiley‐Liss, Inc.


Human Molecular Genetics | 2016

A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development

Anu Bashamboo; Patricia A. Donohoue; Eric Vilain; Sandra Rojo; Pierre Calvel; Sumudu Nimali Seneviratne; Federica Buonocore; Hayk Barseghyan; Nathan C. Bingham; Jill A. Rosenfeld; Surya N. Mulukutla; Mahim Jain; Lindsay C. Burrage; Shweta U. Dhar; Ashok Balasubramanyam; Brendan Lee; Marie-Charlotte Dumargne; Caroline Eozenou; Jenifer Suntharalingham; Ksh de Silva; Lin Lin; Joelle Bignon-Topalovic; Francis Poulat; Carlos F. Lagos; Ken McElreavey; John C. Achermann

Cell lineages of the early human gonad commit to one of the two mutually antagonistic organogenetic fates, the testis or the ovary. Some individuals with a 46,XX karyotype develop testes or ovotestes (testicular or ovotesticular disorder of sex development; TDSD/OTDSD), due to the presence of the testis-determining gene, SRY. Other rare complex syndromic forms of TDSD/OTDSD are associated with mutations in pro-ovarian genes that repress testis development (e.g. WNT4); however, the genetic cause of the more common non-syndromic forms is unknown. Steroidogenic factor-1 (known as NR5A1) is a key regulator of reproductive development and function. Loss-of-function changes in NR5A1 in 46,XY individuals are associated with a spectrum of phenotypes in humans ranging from a lack of testis formation to male infertility. Mutations in NR5A1 in 46,XX women are associated with primary ovarian insufficiency, which includes a lack of ovary formation, primary and secondary amenorrhoea as well as early menopause. Here, we show that a specific recurrent heterozygous missense mutation (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX children and adults from four unrelated families. Remarkably, in one family a sibling raised as a girl and carrying this NR5A1 mutation was found to have a 46,XY karyotype with partial testicular dysgenesis. These unique findings highlight how a specific variant in a developmental transcription factor can switch organ fate from the ovary to testis in mammals and represents the first missense mutation causing isolated, non-syndromic 46,XX testicular/ovotesticular DSD in humans.


American Journal of Medical Genetics Part A | 2008

Additional EFNB1 mutations in craniofrontonasal syndrome

Deeann Wallis; Felicitas Lacbawan; Mahim Jain; Vazken M. Der Kaloustian; Carlos Eduardo Steiner; John B. Moeschler; H. Wolfgang Losken; Ilkka Kaitila; Stephen Cantrell; Virginia K. Proud; John C. Carey; Donald Day; Dorit Lev; Ahmad S. Teebi; Luther K. Robinson; H. Eugene Hoyme; Nadia Al-Torki; Jacqueline Siegel-Bartelt; John B. Mulliken; Nathaniel H. Robin; Dolores Saavedra; Elaine H. Zackai; Maximilian Muenke

Deeann Wallis, Felicitas Lacbawan, Mahim Jain, Vazken M. Der Kaloustian, Carlos E. Steiner, John B. Moeschler, H. Wolfgang Losken, Ilkka I. Kaitila, Stephen Cantrell, Virginia K. Proud, John C. Carey, Donald W. Day, Dorit Lev, Ahmad S. Teebi, Luther K. Robinson, H. Eugene Hoyme, Nadia Al-Torki, Jacqueline Siegel-Bartelt, John B. Mulliken, Nathaniel H. Robin, Dolores Saavedra, Elaine H. Zackai, and Maximilian Muenke* Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland McGill University Health Center, Montreal, Canada Department of Medical Genetics, Unicamp, Campinas, Sao Paulo, Brazil Dartmouth Medical Center, Lebanon, New Hampshire University of Pittsburgh, Pittsburgh, Pennsylvania Haartman Institute, University of Helsinki, Helsinki, Finland New Jersey Dental School, Newark, New Jersey Children’s Hospital of the King’s Daughters, Norfolk, Virginia University of Utah Medical Center, Salt Lake City, Utah Private Practice, Hewitt, Texas Institute of Clinical Genetics, Wolfson Medical Genetics Center, Holon, Israel Weill Cornell Medical College, New York, New York Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York Stanford University School of Medicine, Stanford, California Kuwait Medical Genetics Center, Sulibihkhat, Kuwait The Genetics Institute, Pasadena, California Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts University of Alabama, Birmingham, Alabama Hospital General Dr. Manuel Gea Gonzáles, Mexico City, Mexico Division of Human and Molecular Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania


American Journal of Human Genetics | 2015

Autosomal-Dominant Multiple Pterygium Syndrome Is Caused by Mutations in MYH3

Jessica X. Chong; Lindsay C. Burrage; Anita E. Beck; Colby T. Marvin; Margaret J. McMillin; Kathryn M. Shively; Tanya M. Harrell; Kati J. Buckingham; Carlos A. Bacino; Mahim Jain; Yasemin Alanay; Susan A. Berry; John C. Carey; Richard A. Gibbs; Brendan Lee; Deborah Krakow; Jay Shendure; Deborah A. Nickerson; Gonçalo R. Abecasis; Peter Anderson; Elizabeth Blue; Marcus Annable; Brian L. Browning; Christina T. L. Chen; Jennifer Chin; Gregory M. Cooper; Colleen Davis; Christopher Frazar; Zongxiao He; Preti Jain

Multiple pterygium syndrome (MPS) is a phenotypically and genetically heterogeneous group of rare Mendelian conditions characterized by multiple pterygia, scoliosis, and congenital contractures of the limbs. MPS typically segregates as an autosomal-recessive disorder, but rare instances of autosomal-dominant transmission have been reported. Whereas several mutations causing recessive MPS have been identified, the genetic basis of dominant MPS remains unknown. We identified four families affected by dominantly transmitted MPS characterized by pterygia, camptodactyly of the hands, vertebral fusions, and scoliosis. Exome sequencing identified predicted protein-altering mutations in embryonic myosin heavy chain (MYH3) in three families. MYH3 mutations underlie distal arthrogryposis types 1, 2A, and 2B, but all mutations reported to date occur in the head and neck domains. In contrast, two of the mutations found to cause MPS in this study occurred in the tail domain. The phenotypic overlap among persons with MPS, coupled with physical findings distinct from other conditions caused by mutations in MYH3, suggests that the developmental mechanism underlying MPS differs from that of other conditions and/or that certain functions of embryonic myosin might be perturbed by disruption of specific residues and/or domains. Moreover, the vertebral fusions in persons with MPS, coupled with evidence of MYH3 expression in bone, suggest that embryonic myosin plays a role in skeletal development.


Molecular Genetics and Metabolism | 2014

Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders

Lindsay C. Burrage; Mahim Jain; Laura Gandolfo; Brendan Lee; Mark L. Batshaw; Mendel Tuchman; Marshall L. Summar; Matthias R. Baumgartner; Susan A. Berry; Stephen Cederbaum; George A. Diaz; Annette Feigenbaum; Renata C. Gallagher; Cary O. Harding; Georg Hoffmann; Douglas S. Kerr; Uta Lichter-Konecki; Shawn E. McCandless; J. Lawrence Merritt; Andreas Schulze; Margretta R. Seashore; Tamar Stricker; Susan Waisbren; Derek Wong; Mark Yudkoff; Sandesh C.S. Nagamani

Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n=553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.


American Journal of Physiology-gastrointestinal and Liver Physiology | 2014

Argininosuccinate lyase in enterocytes protects from development of necrotizing enterocolitis

Muralidhar H. Premkumar; Gautam Sule; Sandesh C.S. Nagamani; Smrithi Chakkalakal; Andrew B. Nordin; Mahim Jain; Merry Z Ruan; Terry Bertin; Bryan C Dawson; Jan Zhang; Deborah Schady; Nathan S. Bryan; Philippe M. Campeau; Ayelet Erez; Brendan Lee

Necrotizing enterocolitis (NEC), the most common neonatal gastrointestinal emergency, results in significant mortality and morbidity, yet its pathogenesis remains unclear. Argininosuccinate lyase (ASL) is the only enzyme in mammals that is capable of synthesizing arginine. Arginine has several homeostatic roles in the gut and its deficiency has been associated with NEC. Because enterocytes are the primary sites of arginine synthesis in neonatal mammals, we evaluated the consequences of disruption of arginine synthesis in the enterocytes on the pathogenesis of NEC. We devised a novel approach to study the role of enterocyte-derived ASL in NEC by generating and characterizing a mouse model with enterocyte-specific deletion of Asl (Asl(flox/flox); VillinCre(tg/+), or CKO). We hypothesized that the presence of ASL in a cell-specific manner in the enterocytes is protective in the pathogenesis of NEC. Loss of ASL in enterocytes resulted in an increased incidence of NEC that was associated with a proinflammatory state and increased enterocyte apoptosis. Knockdown of ASL in intestinal epithelial cell lines resulted in decreased migration in response to lipopolysaccharide. Our results show that enterocyte-derived ASL has a protective role in NEC.

Collaboration


Dive into the Mahim Jain's collaboration.

Top Co-Authors

Avatar

Brendan Lee

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard A. Gibbs

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jill A. Rosenfeld

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Maximilian Muenke

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mauricio Arcos-Burgos

Australian National University

View shared research outputs
Top Co-Authors

Avatar

Alyssa A. Tran

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Donna M. Muzny

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge